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The suitability of liposomes as drug carriers in the treatment of drug-resistant rodent malaria was examined
after covalently attaching F(ab*)2 fragments of a mouse monoclonal antibody (MAb), MAb F10, raised against
the host cell membranes isolated from the Plasmodium berghei-infected mouse erythrocytes, to the liposome
surface. The antibody-bearing liposomes thus formed specifically recognized the P. berghei-infected mouse
erythrocytes under both in vitro and in vivo conditions. No such specific binding of the liposomes with the
infected cells was observed when MAb F10 was replaced by another mouse monoclonal antibody, MAb D2. Upon
loading with the antimalarial drug chloroquine, the MAb F10-bearing liposomes effectively controlled not only
the chloroquine-susceptible but also the chloroquine-resistant P. berghei infections in mice. The chloroquine
delivered in these liposomes intravenously at a dosage of 5 mg/kg of body weight per day on days 4 and 6
postinfection completely cured the animals (75 to 90%) of chloroquine-resistant P. berghei infections. These
results indicate that selective homing of chloroquine to malaria-infected erythrocytes may help to cure the
chloroquine-resistant malarial infections with low doses of chloroquine.
Malaria is a serious public health problem which affects
about 300 million people and accounts for 1 million to 2 mil-
lion deaths per year worldwide (22). The disease is being con-
trolled by using antimalarial drugs, like chloroquine, to which
the malarial parasites are rapidly developing resistance (14). In
order to effectively control this disease, it is essential that
newer strategies for treating drug-resistant malaria with exist-
ing drugs be developed.
Liposomes bearing cell-specific recognition ligands on their
surfaces have widely been considered useful as drug carriers in
therapy (5). Our earlier studies have shown that encapsulation
of the antimalarial drug chloroquine (CHQ) in liposomes bear-
ing antierythrocyte antibody on their surfaces markedly in-
creases its efficacy against both CHQ-susceptible and CHQ-
resistant Plasmodium berghei infections in mice (1, 2). Also,
Peeters et al. (12) have reported that liposomization of CHQ
increases not only its maximal tolerable dose but also its effi-
cacy against the CHQ-resistant malarial infections. To further
explore the possibility of using liposomized CHQ in the treat-
ment of CHQ-resistant malaria, we examined the antimalarial
activity of this drug after its encapsulation in liposomes bearing
P. berghei-infected mouse erythrocyte-specific antibody on
their surfaces. Results of the studies indicated that CHQ-re-
sistant malarial infections can be cured with CHQ by delivering
this drug in target-specific liposomes.
MATERIALS AND METHODS
Materials. Egg phosphatidylcholine (egg PC) and gangliosides were prepared
as described earlier (6, 17). Cholesterol was purchased from Centron Research
Laboratory, Bombay, India, and was used after crystallizing it three times from
methanol. Sodium cyanoborohydride and pepsin were bought from Sigma Chem-
ical Company. Sodium metaperiodate was obtained from Sisco Research Labo-
ratory, Bombay, India. Sephadex G-50 and Sepharose 6B were acquired from
Pharmacia Fine Chemicals. [125I]sodium iodide (carrier-free) and [14C]inulin
were procured from Amersham, Buckinghamshire, England. Chloroquine
diphosphate was a kind gift from Walter Reed Army Institute of Research,
Washington, D.C. Normal mouse immunoglobulins (mIg’s) were isolated from
normal mouse serum.
PAbs. Anti-mouse erythrocyte antibodies (polyclonal antibodies [PAbs]) were
raised in rabbits and were isolated from antiserum by following a previously
published procedure (17).
MAbs. BALB/c mice were immunized intraperitoneally (i.p.) at 3-week inter-
vals with the erythrocyte membranes isolated from about 1.5 3 107 mouse
erythrocytes infected predominantly with the trophozoite stage of P. berghei.
Isolation of membranes from infected cells was carried out essentially by our
previously published procedure (8). After four to six immunizations, spleen cells
were fused with PAI-0, a myeloma cell line (19), by using polyethylene glycol (4).
Hybridoma supernatants were screened by immunofluorescence assay with in-
fected erythrocytes as described earlier (13). After cloning by limiting dilutions,
two different clones, F10 and D2, were selected on the basis of their Western
blotting (immunoblotting) patterns by using erythrocyte membranes isolated
from infected cells for ascitic fluid generation. MAbs F10 and D2 were purified
from the ascitic fluids by affinity chromatography with protein A-Sepharose at
pH 8.0. These antibodies were of the IgG1 type as determined by enzyme-linked
immunosorbent assay with isotype-specific antibodies (Sigma Chemical Compa-
ny). The purity of each MAb was confirmed by sodium dodecyl sulfate-polyac-
rylamide gel electrophoresis.
F(ab*)2 fragments and their radioiodination. F(ab9)2 fragments of antibodies
were prepared (17) and radioiodinated (9) by previously published procedures.
Liposomes. Egg PC (20 mmol), cholesterol (20 mmol), and gangliosides (4
mmol) were dissolved in a chloroform-methanol mixture in a thick glass tube, and
the solvents were removed under a slow jet of N2 to give a thin lipid film on the
wall of the tube. The traces of solvents were removed by leaving the tube
overnight under vacuo. It was dispersed in 0.8 ml of borate-buffered saline (10
mM borate, 60 mM NaCl [pH 8.4]) containing CHQ (350 mmol). The dispersion
was sonicated with a probe-type sonicator for 30 min under an N2 atmosphere at
48C. The sonicated preparation was centrifuged in a Beckman L 5-65B ultracen-
trifuge (SW 50.1 rotor) at 105,000 3 g for 1 h at 58C to effect the removal of
titanium particles as well as the poorly dispersed lipids. Only the top two-thirds
of the supernatant was used in further studies. Free CHQ from liposomized
CHQ was separated by gel filtration over Sephadex G-50. The mean outer
diameter of these liposomes, as determined by negative staining electron micros-
copy, was about 60 6 10 nm. The liposomes used for in vitro or in vivo binding
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with erythrocytes were also prepared as described above, except that in place of
CHQ [14C]inulin was used in the dispersion buffer.
Covalent coupling of F(ab*)2 with liposomes.
125I-labelled (or unlabelled)
F(ab9)2 fragments from PAbs, MAb F10, MAb D2, and mIg were covalently
attached to liposomes as reported earlier (17). Briefly, the liposomes containing
CHQ were subjected to periodate oxidation for generating aldehyde groups from
gangliosides. After removing the excess periodate, the oxidized liposomes were
reacted with the free amino group(s) of F(ab9)2 fragments, and the labile Schiff’s
base thus formed was stabilized by reducing it with sodium cyanoborohydride.
The protein-to-lipid ratio in the immunoliposomes obtained by this procedure
was about 80 mg/mmol of lipid P.
CHQ estimation. CHQ was estimated as described earlier (1) by measuring
the A342. The amount of CHQ associated with liposomes was about 140 6 3 mg
of CHQ/mmol of lipid P.
Animals. Randomly bred 8- to 10-week-old male Swiss or BALB/c mice
(weight, 20 6 2 g) were used in the study. The animals were given pellet diet
(Hindustan Lever Ltd., Bombay, India) and water ad libitum.
Parasites. P. berghei parasites were obtained from the National Institute of
Communicable Diseases, New Delhi, India, and were maintained in the Swiss
mice through serial blood passage. The strain was fully susceptible to CHQ, with
the 90% effective dose being 15 mg/kg of body weight given consecutively for 4
days (i.p.). Parasitemia was determined by counting 103 erythrocytes in thin
blood smears stained with Giemsa and was expressed as the number of parasit-
ized cells per 100 erythrocytes.
Development of CHQ resistance. CHQ resistance was developed by the re-
lapse technique (21). Randomly bred Swiss mice were infected with about 107 P.
berghei-infected erythrocytes, and on the same day a single dose (60 mg/kg, i.p.)
of CHQ was administered. After the animals developed about 2% parasitemia,
the infected blood from these animals was transfused into healthy animals, which
were also given CHQ (60 mg/kg, i.p.) simultaneously. The operation described
above was repeated several times until the organisms causing the infection were
rendered resistant to CHQ (50 mg/kg given consecutively for 4 days, i.p.).
Liposome binding to erythrocytes in vitro. Blood (5 ml) from P. berghei-
infected and healthy uninfected BALB/c mice was drawn in heparinized glass
tubes containing phosphate-buffered saline (10 mM NaCl [pH 7.4]). It was
passed through a CF-11 column (5 ml) to remove leukocytes. Infected and
normal erythrocytes were separated by Ficoll-Conray gradient. The gradient was
prepared by mixing Conray 420 (33% [wt/vol] solution in water on the basis of
the sodium iothalamate content) to a 9% solution of Ficoll 400 in normal saline
until the density of the mixture was 1.08 g/ml. A total of 1 ml of the cell
suspension (50% hematocrit) was carefully layered on the top of 2 ml of gradient
in a glass tube (5 ml). It was centrifuged at 300 3 g for 10 min at 20 6 28C.
Infected cells were aspirated from the top and washed several times with Tris-
buffered saline (TBS; 10 mM Tris containing 150 mM NaCl [pH 7.4]). The
infected erythrocyte preparation thus obtained was contaminated with #3%
normal erythrocytes.
Erythrocytes (about 65 3 106 cells) were incubated with liposomes (100 to 500
nmol of lipid P), doubly radiolabelled by attaching 125I-labelled F(ab9)2 frag-
ments to the liposome surface, and entrapping [14C]inulin in the aqueous com-
partment in sucrose-supplemented TBS (750 ml) at 378C for 30 min. After
completing the incubation, the cells were pelleted and washed extensively with
ice-cold, sucrose-supplemented TBS. The amount of cell-associated 125I was
determined without disrupting the cells, whereas for measuring 14C, the cells
were lysed with Triton X-100. The amounts of measured 14C were duly corrected
for quenching by hemoglobin.
Distribution of liposomes in tissue. Doubly radiolabelled liposomes (0.75 to
1.25 mmol of lipid P, 250 ml) were injected into the tail veins of healthy and P.
berghei-infected (50 to 60% parasitemia) BALB/c mice. Animals were sacrificed
immediately after drawing about 1 ml blood at 30 min postinjection, and the
various organs (liver, spleen, lung, kidney, and heart) were removed, washed,
blotted, and weighed. A 10% (wt/vol) homogenate of these organs was prepared
in sucrose-supplemented TBS. The homogenate was centrifuged at 5,000 3 g,
and measured aliquots of the supernatant were used for determining the radio-
activity. The amounts of radioactivity associated with plasma and erythrocytes
were determined as follows.
Blood (1 ml) was centrifuged, and the volumes of the plasma and cell pellet
thus separated were measured. Plasma was collected in a glass tube, and the cell
pellet was washed with TBS. The radioactivity in known aliquots of cells and
plasma was determined by counting the 14C and 125I. The amounts of radioac-
tivity associated with plasma and cells (predominantly erythrocytes) in vivo were
calculated by assuming that the total blood volume was 8% of the body weight
(18).
Drug treatment. Several preparations of CHQ-containing liposomes were
evaluated for their efficacies. Swiss mice (6 to 10 animals per group) were
injected on day zero with about 106 erythrocytes infected with CHQ-susceptible
or CHQ-resistant P. berghei strains. The treatment was started on day 4 postin-
fection when the parasitemia in the animals reached 0.1 to 0.5%. The animals
were observed on various days for parasitemia. The percent suppression of
parasitemia in CHQ-treated animals was calculated by comparing the para-
sitemia in these animals with that in animals treated under identical conditions
with buffer.
Statistical analysis. Statistical significance (P value) was ascertained by per-
forming t tests on both the parasitemia and survival data by using Sigma plot
statistics software package (Sigmaplot Scientific Graphing System).
RESULTS
Two MAbs (D2 and F10), which recognized P. berghei-in-
fected mouse erythrocytes, were covalently attached to the
surfaces of [14C]inulin-containing liposomes after removing
their Fc portion by pepsin treatment and labelling the resulting
F(ab9)2 fragments with
125I. The antibody-bearing liposomes
(MAb D2-Lip and MAb F10-Lip) thus obtained were inter-
acted with normal and P. berghei-infected mouse erythrocytes
in vitro in order to assess their binding specificities. The bind-
ing was determined by measuring the cell-associated 125I and
14C. Liposomes bearing F(ab9)2 of normal mIg on their sur-
faces (mIg-Lip) were used as controls. The results given in Fig.
1 indicate that MAb D2-Lip could bind to both normal and
infected erythrocytes. Unlike this finding, no such nonspecific
binding was observed with MAb F10-Lip. These liposomes rec-
ognized only the infected cells but not the normal erythrocytes.
The maximum binding of MAb F10-Lip observed with P.
berghei-infected erythrocytes was about 16%, in comparison
with #3% binding observed with normal cells.
To further confirm the specificity of MAb F10-Lip binding
with infected erythrocytes, the liposome preparations de-
scribed above were administered intravenously to healthy and
P. berghei-infected (50 to 60% parasitemia) BALB/c mice, and
their distributions in various tissues were determined. Figure 2
shows that, unlike MAb D2-Lip, MAb F10-Lip did not signifi-
cantly bind to the erythrocytes in healthy animals, but it readily
recognized these cells in P. berghei-infected mice. These results
thus clearly established that MAb F10-Lip recognized specifi-
cally the infected erythrocytes.
The suitability of MAb F10-Lip as a drug carrier in the
treatment of malarial infections was examined by loading these
liposomes with CHQ and then evaluating the efficacies of the
CHQ-loaded liposomes against P. berghei infections in Swiss
mice. Table 1 shows that the efficacy of CHQ against CHQ-
susceptible P. berghei infections was considerably increased (P
, 0.001) by delivering this drug in antibody-bearing liposomes.
The best results were observed when CHQ was delivered at a
dose of 5.0 mg/kg. At this dose, CHQ encapsulated in MAb
F10-Lip effectively controlled not only the CHQ-susceptible
but also the CHQ-resistant P. berghei infections (Table 2).
The experiments described above were carried out by ad-
ministering only one dose of CHQ to the infected mice. To
examine whether increasing the number of CHQ doses would
completely cure the treated animals of malarial infections, we
delivered to the CHQ-resistant P. berghei-infected mice two
doses of liposomized CHQ on days 4 and 6 postinfection.
Table 3 shows that in the MAb F10-Lip–CHQ-treated group,
75 to 90% of the animals survived the CHQ-resistant P. berghei
infections and no parasites were detectable in their blood even
on day 30 posttreatment. Unlike this observation, only 40 to
50% of the animals in the MAb D2-Lip–CHQ-treated group,
which were treated under identical conditions, survived.
DISCUSSION
The present study demonstrates that grafting of MAb F10 on
the liposome surface enables the liposomes to selectively rec-
ognize the P. berghei-infected mouse erythrocytes under both
in vitro and in vivo conditions. Another MAb, MAb D2, al-
though it recognized the infected erythrocytes as well as MAb
F10 did, at least under in vitro conditions, was not very specific
to these cells because it also readily recognized the normal
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mouse erythrocytes. From these results it would appear that
MAb F10 perhaps recognizes some surface antigen which is
unique to the P. berghei-infected erythrocytes, whereas MAb
D2 may possibly be binding some surface determinant which
could be common to both the normal and infected cells.
Earlier studies have shown that the intracellular malarial
parasite modifies the membrane protein composition in the
host erythrocytes (15). On one hand, it structurally alters the
native erythrocyte membrane proteins (16), while on the other,
it inserts some new proteins in the plasma membrane of the
host cell (7, 11). It is therefore tempting to speculate that MAb
F10 might have been directed against some new protein(s) of
parasite origin, whereas MAb D2 could be recognizing some
modified erythrocyte component in infected cells.
The present study shows that the antimalarial activity of
CHQ is markedly increased by encapsulating this drug in MAb
FIG. 1. Binding of liposomes to erythrocytes in vitro expressed as a percent-
age of the total 14C or 125I associated with 653 106 erythrocytes. The 14C binding
is not shown here for the sake of clarity. (A) mIg-Lip; (B) MAb D2-Lip; (C) MAb
F10-Lip. The open and closed circles represent binding with P. berghei infected
and normal uninfected mouse erythrocytes, respectively. Values are means 6
standard deviations of three determinations.
FIG. 2. Distribution of liposomes in various organs and tissues. Liposomes
containing 125I-labelled F(ab9)2 on their surfaces and [14C]inulin in their aqueous
compartments were injected separately to healthy (A) and P. berghei-infected (B)
mice, and their distributions in various tissues were determined 30 min after the
injection. Only the 125I distributions are shown for the sake of clarity. Values are
means 6 standard deviations for three animals. Open bars, mIg-Lip; solid bars,
MAb D2-Lip; shaded bars, MAb F10-Lip; RBC, erythrocytes.
TABLE 1. Efficacy of CHQ against CHQ-susceptible P. berghei
infections in mice after encapsulating CHQ in liposomes
Treatment and
comparison groupa
Dose
(mg/kg)
% Parasitemia
on day 10
posttreatmentb:
Saline 19.50 6 0.50 (2)
Free CHQ 5.0 7.90 6 2.90 (5)
mIg-Lip–CHQ 5.0 6.44 6 1.80 (5)
PAb-Lip–CHQ 5.0 0.65 6 0.30 (6)
2.5 2.50 6 1.20 (6)
1.0 4.33 6 1.50 (6)
MAb D2-Lip–CHQ 5.0 0.68 6 0.25 (6)
2.5 1.80 6 1.20 (6)
1.0 4.50 6 1.70 (6)
MAb F10-Lip–CHQ 5.0 0.44 6 0.25 (6)
2.5 1.40 6 0.98 (6)
1.0 4.02 6 1.20 (6)
P value
Free CHQ vs PAb-Lip–CHQ 5.0 ,0.001
Free CHQ vs MAb D2-Lip–CHQ 5.0 ,0.001
Free CHQ vs MAb F10-Lip–CHQ 5.0 ,0.001
PAb-Lip–CHQ vs MAb D2-Lip–CHQ 2.5 .0.1
PAb-Lip–CHQ vs MAb F10-Lip–CHQ 2.5 ,0.1
MAb D2-Lip–CHQ vs MAb F10-Lip–CHQ 2.5 .0.1
a Treatment was given intravenously only once on day 4 after the infection.
Each group consisted of six animals.
b Values are means 6 standard deviations. Figures given in parentheses de-
note the numbers of animals surviving on day 10.
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F10-Lip. MAb F10-Lip–CHQ controlled efficiently not only the
CHQ-susceptible P. berghei infections but also the infections
that were otherwise resistant to the CHQ treatment. The high
therapeutic efficacy of liposomized CHQ observed here could
primarily be attributed to the following factors: (i) the high
degree of specificity of MAb F10-Lip to the malaria-infected
erythrocytes, (ii) the specific binding of MAb F10-Lip possibly
to free parasites, and (iii) the efficient internalization of the
cell-bound MAb F10-Lip. This finds strong support from our
present observations that (i) in spite of the similar extents of
bindings of MAb D2-Lip and MAb F10-Lip to the infected
erythrocytes, MAb D2-Lip–CHQ showed considerably lower
levels of antimalarial activity in comparison with those of MAb
F10-Lip–CHQ and (ii) MAb F10-Lip alone, without CHQ, did
not exhibit the antimalarial activity (unpublished data).
It is interesting to observe that the CHQ-resistant malarial
infection can be cured with CHQ by encapsulating it in target-
specific liposomes. Because one of the reasons for parasite
resistance to CHQ has been attributed to the enhanced efflux
of CHQ from the resistant parasites, preventing intracellular
TABLE 2. Efficacy of CHQ against CHQ-resistant P. berghei infections in mice after its encapsulation in liposomes
Treatment and
comparison groupa
% Parasitemia on the following day posttreatmentb:
6 8 10
Saline 1.57 6 0.38 (5) 4.33 6 0.90 (3) All dead
Free CHQ 1.70 6 0.87 (5) 4.20 6 1.80 (3) All dead
PAb-Lip–CHQ 1.36 6 0.34 (6) 3.40 6 0.75 (5) 6.80 6 1.20 (2)
MAb D2-Lip–CHQ 1.20 6 0.39 (6) 3.23 6 0.73 (6) 4.56 6 1.40 (3)
MAb F10-Lip–CHQ 1.12 6 0.20 (6) 1.58 6 0.26 (6) 2.58 6 1.10 (6)
P value
Free CHQ vs PAb-Lip–CHQ .0.1 .0.1
Free CHQ vs MAb D2-Lip–CHQ .0.1 .0.1
Free CHQ vs MAb F10-Lip–CHQ .0.1 ,0.05
PAb-Lip–CHQ vs MAb D2-Lip–CHQ .0.1 .0.1 .0.1
PAb-Lip–CHQ vs MAb F10-Lip–CHQ .0.1 ,0.001 ,0.01
MAb D2-Lip–CHQ vs MAb F10-Lip–CHQ .0.1 ,0.001 ,0.1
a Treatment with CHQ (5 mg/kg) was given intravenously only once on day 4 after the infection. Each group consisted of seven animals.
b Values are means 6 standard deviations. Figures given in parentheses denote the numbers of animals surviving on that particular day.
TABLE 3. Efficacy of CHQ against CHQ-resistant P. berghei infections in mice after encapsulating it in liposomes
Treatment and
comparison groupa
% Parasitemia on the following
day posttreatmentb:
Survival on day 30 post treatment
(no. of surviving mice/total
no. tested)8 30
Saline 4.16 6 1.03 All dead 0/8
4.28 6 0.62 All dead 0/8
5.90 6 2.30 All dead 0/10
Free CHQ 4.50 6 0.95 All dead 0/8
6.30 6 1.94 All dead 0/8
5.30 6 0.92 All dead 0/10
PAb-Lip–CHQ 2.80 6 0.62 0.00 3/8
2.75 6 1.40 0.00 4/8
2.15 6 0.69 0.05 6 0.08 4/10
MAb D2-Lip–CHQ 1.58 6 0.43 0.00 4/8
1.67 6 0.48 0.00 4/8
1.80 6 0.71 0.02 6 0.04 4/10
MAb F10-Lip–CHQ 0.97 6 0.19 0.00 7/8
0.81 6 0.26 0.00 6/8
1.15 6 0.25 0.00 8/10
P-value
PAb-Lip–CHQ vs MAb D2-Lip–CHQ ,0.01 .0.1
c
.0.05
.0.05
PAb-Lip–CHQ vs MAb F10-Lip–CHQ ,0.001 ,0.01
,0.01
,0.01
MAb D2-Lip–CHQ vs MAb F10-Lip–CHQ ,0.05 ,0.01
,0.01
,0.05
a Treatments with CHQ (5 mg/kg/day) were given intravenously on days 4 and 6 after infection. Three independent experiments were carried out for each treatment
group.
b Values are means 6 standard deviations.
c P values for survival data were calculated by pooling the data from all three experiments.
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concentrations from achieving toxic levels (3, 10, 20), we infer
that the CHQ delivered through MAb F10-Lip could be reach-
ing the infected cells in quantities sufficient to kill the intra-
cellular parasite. This could indeed be the case, since delivery
of CHQ in MAb F10-Lip should help to concentrate the drug
in infected cells not only by the selective recognition of these
cells but also by the ability of liposomes to deliver several drug
molecules at a time to the target cells.
Peeters et al. (12) have shown that encapsulation of CHQ in
liposomes (nontargeted) increases not only the maximal toler-
able dose from 0.8 to 10 mg of CHQ per animal when given i.p.
but also the effectiveness of the drug against both the CHQ-
susceptible and CHQ-resistant P. berghei infections. A dose of
8 mg per mouse per day for 3 consecutive days was found to be
the most effective, which was at least 80 times greater (assum-
ing that the average weight of a mouse is about 20 g) than the
CHQ dose used in the present study. From these findings we
conclude that the therapeutic efficacy of CHQ can be markedly
increased by delivering this drug through target-specific lipo-
somes.
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